• Home
• News
• About Us
• Contact

Cangene signs extension for botulism antitoxin contract
by Tina Redlup on March 31, 2010

A no-cost modification has been signed by Cangene Corporation to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority.

HGS and BioInvent announce collaboration
by Pat Dulnier on March 12, 2010

Human Genome Sciences, Inc., and BioInvent International AB have announced a collaboration meant to discover, develop and commercialize therapeutic monoclonal antibodies that have would specifically target antigens discovered by HGS.

Human Genome Sciences' CFO resigns
by Rita Uplend on March 4, 2010

Human Genome Sciences Inc., which is developing an inhalational anthrax treatment, has announced this week that Chief Financial Officer Timothy Barabe is resigning.

Aradigm advances work on inhaled lipsomal ciprofloxacin
by Nick Rees on February 24, 2010

Aradigm Corporation has announced that is has dosed its first U.S. patient as part of its Once-daily Respiratory Bronchiectasis Inhalation Treatment trial.

Nanomaterials could be key to fighting airborne biothreat
by Nick Rees on February 23, 2010

Nanomaterials developed at Montana State University could be used in the future to fight respiratory infections created by bioattacks, scientists have said.

Scott Habig joins Human Genome Sciences
by Nick Rees on February 3, 2010

Scott Habig has joined Human Genome Sciences, Inc., as vice president of sales.

Aethlon Medical advances therapeutic device for biological warfare pathogens
by Pat Dulnier on January 14, 2010

A company developing a therapeutic device meant to treat acute and chronic viral infections, biological warfare pathogens and other conditions has issued a research update.

Contract awarded for inhalation anthrax medication
by Nick Rees on December 24, 2009

The Biomedical Advanced Research and Development AUthority has awarded Pine Brook, N.J.-based Elusys Therapeutics, Inc., a contract for the advanced development of a medication to treat inhalational anthrax.

India prepares for bioattacks at 2010 Commonwealth Games
by Nick Rees on December 24, 2009

Almost eight battalions of India's National Disaster Response Force have readied themselves with prophylaxis for anthrax and nerve gas antidotes in preparation for the 2010 Commonwealth Games that will take place in New Delhi.

XOMA Ltd., announces advances in neutralizing botulinum neurotoxin Type A
by Nick Rees on December 11, 2009

XOMA Ltd. has announced results that demonstrate its monoclonal antibody technology XOMA 3AB's ability to neutralize botulinum neurotoxin Type A, a bioterror threat that causes paralysis.

Autophay-inducing agent shown to neutralize tularemia
by Nick Rees on December 10, 2009

A recent study in the Journal of Biomedical Science has revealed that an autophagy-inducing agent introduced to the bacteria that causes tularemia in humans can eradicate the small-molecule agents that target innate immunity.

First ricin antidote moves into production phase
by Daniel Purt on November 18, 2009

Scientists at the British government and military park Porton Down have announced the development of an antidote to the poison ricin that they say is ready to be manufactured.

Search

Subscribe to our newsletter

RSS Feed